Medinet (2370) · RiskMaterialised
Delayed Benefits from Sales Expansion and R&D Investment
First written in FY2017-Q3. 2 of 2 entries say "Materialised", first in FY2017-Q3. Latest entry: FY2017.
2entries
1years
0from disclosures
How it moved
Same theme, other companies
Impairment of investment assets due to delays in technological innovation and business expansionA theme 4 companies write about · 4 as a headwind · 0 as a tailwind
Medinet moved to the "Worse" side of this theme in 2017.
1 other company's latest entry also says "Materialised".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2017MaterialisedAnnual report
「As the outlook for monetising the cell therapy products business required more time, impairment indicators were identified at a larger unit including shared assets. The carrying amounts of these assets were therefore reduced to their recoverable amounts, and the resulting reduction of ¥880.958 million was recognised as an impairment loss under extraordinary losses.」
The delayed benefits from R&D and sales investment materialised as delays in monetising the cell therapy products business and an impairment loss of ¥880.958 million. - FY2017-Q3MaterialisedAnnual report
「This was because it was taking longer than expected for these initiatives to produce results.」
Although the Company increased staffing for sales activities and R&D expenses for the cell therapy products business, the benefits of those investments have taken longer than expected to emerge.